CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Stock Information for Elevation Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Elevation Oncology Inc.

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.